midostaurin (Rydapt)
Jump to navigation
Jump to search
Indications
- acute myeloid leukemia (AML), FLT3 mutation positive
- for use in combination with standard cytarabine & daunorubicin induction & cytarabine consolidation
- aggressive systemic mastocytosis or systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia
Dosage
- AML:
- 50 mg every 12 hours* on days 8-21 of each induction cycle with cytarabine & daunorubicin & on days 8-21 of each consolidation cycle with high-dose cytarabine
- systemic mastocytosis or mast cell leukemia:
* with food
Capsules: 25 mg
Adverse effects
- >= 20%
- febrile neutropenia
- nausea, vomiting
- mucositis
- headache
- petechiae
- musculoskeletal pain
- epistaxis
- device-related infection
- hyperglycemia
Drug interactions
- strong CYP3A4 Inhibitors may increase exposure to midostaurin & its active metabolite
Mechanism of action
- inhibits FLT3 receptor tyrosine kinase
More general terms
References
- ↑ Gotlib J, Kluin-Nelemans HC, George TI et al Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2530-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27355533 Free Article
- ↑ O'Neil A, Klil-Drori AJ. AML: FLT3 Inhibitor Shows 'Robust' Activity as Frontline Therapy - Overall response rate 100% in patients with FLT3- mutated disease in early research. MedPage Today. Jan 17, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70559
- ↑ RYDAPT prescribing information https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/rydapt.pdf
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9829523
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=24202429
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16760627
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=59476509
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71719722
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71311854
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=101631538